The prestigious National Taiwan University (NTU) will lead a large-scale lung cancer study. Led by Professor Chen Jin-Shing in the Department of Surgery, the study will include 1,200 patients receiving low-dose computed tomography scans, including 1,000 with lung cancer.
The clinical sponsor is publicly traded VolitionRx Limited NYSE AMERICAN: VNRX). Founded in 2010, Singapore-based VolitionRx develops easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid. They seek to diagnose a range of cancers quickly and cost effectively.
CEO Dr. Jasmine Kway reported “we are delighted with the progress we have achieved with the network of key influencers and collaborators in Asia and in particular our expanded relationship with National Taiwan University.” Interestingly, the actual cost of the study with NTU is quoted by Kway at $360,000 over a two-year period as she was emphasizing their ability to structure large and economical studies.
NTU will be utilizing VolitionRx’s Nu.Q™ in this large study. Professor Chin Jin Shing noted that the “early data from Nu.Q™ technology platform is promising, and clearly large scale studies are required. We are delighted to execute this agreement and very much look forward to evaluating the Nu.Q™ technology platform.”
CEO Kway is hopeful that VolitionRx’s recent proof of concept lung cancer study results are repeated with the much larger cohort to be tested by NTU. The recent proof of concept studies included:
- Lung cancer cohort (76 participants); a single Nu.Q™ assay detected lung cancer, including stage I lung cancer. The Area Under the Curve (AUC) for this single assay was 85%, cancer vs. healthy
- Second confirmatory lung cancer cohort (152 participants), the same single Nu.Q™ assay also detected lung cancer with AUC of 79%, cancer vs. healthy
VolitionRx has also recently executed a nonbinding Memorandum of Understand with Shanghai Fosun Long March Medical Science Co., Ltd. With the shared target to enter into a binding agreement to conduct three small-scale clinical trials in China. One of the trials is in lung cancer, and the others are in colorectal cancer and ovarian cancer with preliminary data expected in 2019.